Sign In
Buy ELMD
Electromed Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | $0.260 |
| EPS actual | $0.350 |
| EPS Surprise | 34.62% |
| Revenue estimate | 17.6M |
| Revenue actual | 18.575M |
| Revenue Surprise | 5.54% |
| Release date | Feb 10, 2026 |
| EPS estimate | $0.270 |
| EPS actual | $0.320 |
| EPS Surprise | 18.52% |
| Revenue estimate | 18.049M |
| Revenue actual | 18.897M |
| Revenue Surprise | 4.70% |
| Release date | Nov 12, 2025 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS Surprise | 13.64% |
| Revenue estimate | 18.3M |
| Revenue actual | 16.887M |
| Revenue Surprise | -7.72% |
| Release date | Aug 26, 2025 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS Surprise | 13.64% |
| Revenue estimate | 16.341M |
| Revenue actual | 17.393M |
| Revenue Surprise | 6.44% |
Last 4 Quarters for Electromed
Below you can see how ELMD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 26, 2025 |
| Price on release | $20.66 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS surprise | 13.64% |
| Date | Price |
|---|---|
| Aug 20, 2025 | $19.61 |
| Aug 21, 2025 | $19.02 |
| Aug 22, 2025 | $20.27 |
| Aug 25, 2025 | $20.20 |
| Aug 26, 2025 | $20.66 |
| Aug 27, 2025 | $24.77 |
| Aug 28, 2025 | $24.53 |
| Aug 29, 2025 | $24.73 |
| Sep 02, 2025 | $23.95 |
| 4 days before | 5.35% |
| 4 days after | 15.92% |
| On release day | 19.89% |
| Change in period | 22.13% |
| Release date | Nov 12, 2025 |
| Price on release | $25.38 |
| EPS estimate | $0.220 |
| EPS actual | $0.250 |
| EPS surprise | 13.64% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $24.34 |
| Nov 07, 2025 | $24.17 |
| Nov 10, 2025 | $24.30 |
| Nov 11, 2025 | $25.00 |
| Nov 12, 2025 | $25.38 |
| Nov 13, 2025 | $26.35 |
| Nov 14, 2025 | $25.16 |
| Nov 17, 2025 | $24.63 |
| Nov 18, 2025 | $24.52 |
| 4 days before | 4.27% |
| 4 days after | -3.39% |
| On release day | 3.82% |
| Change in period | 0.740% |
| Release date | Feb 10, 2026 |
| Price on release | $28.06 |
| EPS estimate | $0.270 |
| EPS actual | $0.320 |
| EPS surprise | 18.52% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $29.23 |
| Feb 05, 2026 | $29.00 |
| Feb 06, 2026 | $29.11 |
| Feb 09, 2026 | $27.61 |
| Feb 10, 2026 | $28.06 |
| Feb 11, 2026 | $25.26 |
| Feb 12, 2026 | $23.31 |
| Feb 13, 2026 | $24.26 |
| Feb 17, 2026 | $25.34 |
| 4 days before | -4.00% |
| 4 days after | -9.69% |
| On release day | -9.98% |
| Change in period | -13.31% |
| Release date | May 12, 2026 |
| Price on release | $27.20 |
| EPS estimate | $0.260 |
| EPS actual | $0.350 |
| EPS surprise | 34.62% |
| Date | Price |
|---|---|
| May 06, 2026 | $25.94 |
| May 07, 2026 | $26.86 |
| May 08, 2026 | $26.93 |
| May 11, 2026 | $25.93 |
| May 12, 2026 | $27.20 |
| May 13, 2026 | $34.03 |
| May 14, 2026 | $36.50 |
| May 15, 2026 | $35.68 |
| May 18, 2026 | $38.24 |
| 4 days before | 4.86% |
| 4 days after | 40.59% |
| On release day | 25.11% |
| Change in period | 47.42% |
Electromed Earnings Call Transcript Summary of Q1 2026
Electromed reported a strong start to fiscal 2026 with twelfth consecutive quarter of year‑over‑year revenue and profit growth. Q1 revenue was $16.9 million, up 15% year‑over‑year, driven by broad‑based growth across direct home care (+13%), distributors (+41%), and hospitals (+52%). Operating income rose 38% to $2.7 million (15.8% of revenue) and diluted EPS was $0.25. Gross margin remained in the mid‑70s (~78% of revenue). The company continues to invest in commercial infrastructure (expanded home care sales force to 57 reps), clinical education, and market development (Triple Down on Bronchiectasis campaign and CEU webinars). Electromed launched a new CRM and completed a manufacturing optimization with no fulfillment disruptions, and more than one‑third of orders are now e‑prescribed. The board authorized a $10 million share repurchase program and the company finished the quarter with $14.1 million cash, $24.8 million AR, no debt, and $44.7 million shareholders’ equity. Management emphasized a large addressable opportunity — ~923,000 diagnosed bronchiectasis patients in the U.S. with only ~6% using HFCWO therapy (an immediate opportunity of ~800,000 patients), plus millions potentially undiagnosed — and plans continued measured investment in the hospital channel while keeping home care the core focus.
